UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Catabasis Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware (State of incorporation or organization)

26-3687168 (I.R.S. Employer Identification No.)

 

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered		Name of each exchange on which each class is to be registered
Common stock, par value $0.001 per share		The NASDAQ Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. o

 

Securities Act registration statement file number to which this form relates:   333-204144

 

Securities to be registered pursuant to Section 12(g) of the Act:  None.

 

 

 

Item 1.  Description of Registrant’s Securities to be Registered.

 

The description under the heading “Description of Capital Stock” relating to the Registrant’s common stock, par value $0.001 per share, in the prospectus included in the Registrant’s Registration Statement on Form S-1 (File No. 333-204144), as amended (the “Registration Statement”), filed under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “Commission”) is incorporated herein by reference.  Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.

 

Item 2.  Exhibits.

 

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Global Market and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

2

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

	Catabasis Pharmaceuticals, Inc.
	By:	/s/ Jill C. Milne
		Jill C. Milne, Ph.D.
		President and Chief Executive Officer
Dated: June 22, 2015

 

3